Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594824 | 1.00 | BMP1 (0.43) | BMP1MMP12 | |
| SCHEMBL1594823 | 1.00 | BMP1 (0.43) | BMP1MMP12 | |
| SCHEMBL1596366 | 0.92 | BMP1 (0.34) | BMP1MMP12 | |
| SCHEMBL1596376 | 0.92 | BMP1 (0.34) | BMP1MMP12 | |
| SCHEMBL1595379 | 0.90 | BMP1 (0.34) | BMP1MMP12 | |
| SCHEMBL1595372 | 0.90 | BMP1 (0.34) | BMP1MMP12 | |
| SCHEMBL1597039 | 0.89 | BMP1 (0.33) | BMP1MMP12 | |
| SCHEMBL1597036 | 0.89 | BMP1 (0.33) | BMP1MMP12 | |
| SCHEMBL1595986 | 0.89 | BMP1 (0.52) | BMP1MMP12 | |
| SCHEMBL1595988 | 0.89 | BMP1 (0.52) | BMP1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1827449-A4 | THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1827449-A2 | THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006055663-A2 | THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | MRPL21, NRDC, SPOUT1 | BMP1 1513/4885MMP12 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.